Faheem Hasnain at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)
July 13, 2022 07:00 AM EDTUpdated July 15, 12:34 PM
Deals
Bioregnum

Fa­heem Has­nain forges a $120M pri­vate place­ment. So what did we learn from that?

This morn­ing Fa­heem Has­nain is un­veil­ing a $120 mil­lion pri­vate place­ment for his biotech, Gos­samer Bio. Which says a lot about where and how the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times